We Develop Drug Treatments Using Physics Based Modeling and
Kevin Short, PhD
Head of Chemistry
Kevin joined Verseon because his life goal is to see the largest possible number
of new chemical entities with novel modes of action become life-changing drugs.
He is instrumental in guiding Verseon’s medicinal chemistry campaigns and IP
strategy for protecting Verseon’s novel drug candidates. Kevin has also run
medicinal chemistry programs at Johnson & Johnson and Ontogen. He is an inventor
on 8 patents. Kevin received his BS from Imperial College and his PhD in
Chemistry from the University of Exeter.